The OCEAN Trial found that rivaroxaban did not significantly reduce the incidence of stroke, systemic embolism, or new covert embolic events compared with aspirin in patients at high risk for stroke ...
As the new year begins, the landscape of cardiovascular medicine is undergoing a remarkable transformation, driven by groundbreaking technologies and innovative approaches that promise to ...
About 50% of U.S. adults will develop high BP during their lifetime. High BP is the most prevalent and modifiable risk factor for cardiovascular disease and all-cause mortality. The overarching BP ...
Digital HWC programs (human coaching supported with digital tools) are structured, evidence-based and increasingly delivered via telehealth. 4,11 These programs begin with the enrollment and risk ...
Global death counts due to cardiovascular disease (CVD) increased from 12.4 million in 1990 to 19.8 million in 2022, reflecting global population growth and aging and the contributions from ...
In recent years, numerous health care challenges have been tackled, some making headlines, while others quietly escalate under the radar – like polypharmacy. Cardiovascular medications frequently lead ...
The ACC has named Renuka Jain, MD, FACC, as the incoming chair-elect of its Board of Governors, beginning April 2025 following ACC.25 in Chicago, IL. She will replace David E. Winchester, MD, MS, FACC ...
US and international guidelines advocate for the achievement of very low levels of LDL-C, particularly for individuals at highest risk. The concerns about stroke and cognitive issues with very low LDL ...
The ACC's Guideline Clinical App is the mobile home of clinical guideline content and tools for clinicians caring for patients with cardiovascular disease. The App brings the guidelines closer to the ...
Four major studies presented at AHA 2025 are reshaping strategies for managing atrial fibrillation (AFib) in complex clinical scenarios. OCEAN addresses whether ongoing anticoagulation is necessary ...
The newest clinical guideline released by the ACC and the American Heart Association (AHA) provides new and updated recommendations for preventing and optimally managing atrial fibrillation (AFib).
Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results